{Reference Type}: Journal Article
{Title}: COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2.
{Author}: Shah SMI;Yasmin F;Memon RS;Jatoi NN;Savul IS;Kazmi S;Monawwer SA;Zafar MDB;Asghar MS;Tahir MJ;Lee KY;
{Journal}: Brain Behav
{Volume}: 12
{Issue}: 12
{Year}: 12 2022
暂无{DOI}: 10.1002/brb3.2789
{Abstract}: This review highlights the potential mechanisms of neuromuscular manifestation of COVID-19, especially myasthenia gravis (MG).<BR>An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020.<BR>Exacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID-19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders.<BR>Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.